View this email in your browser


To our CBTN partners,

We have some exciting news! Please join us in
congratulating Jena Lilly, who was unanimously named as Executive Director of the CBTN by the Executive Board. All of her hard work and dedication to our vision and mission to help our children is awe inspiring. The CBTN would certainly not be where it is today without her. Congratulations, Jena!

Childhood Cancer Awareness Month was fantastic. CBTN raised over $25,000 through the CHOP Parkway Run Brain Tumor Avengers team

The restructure is moving along! We hope you found the
CBTN FY20 goals report, FY21 goals plan, and FY20 Budget report informative. Please provide questions and feedback by October 9th to allow us to get the reports finalized. The CBTN FY21 Budget plan and the CBTN FY20 Communications Report and FY21 plan will be circulated later in October for your review and feedback. We will also be reaching out to begin to schedule 1-1 calls to discuss your participation in the CBTN Membership levels in November and are so happy the CBTN Community Sessions have launched!

Thank you for those who have participated in website review meetings! Our goal is to
launch Version 1 of the website in October! The website will still have the feedback function available, so please send any comments and share that with your communities. 

Don’t forget to  register for the
Fall Public CBTN Investigator Meeting! This meeting is open to all so please share with your communities! We are excited to have the investigators share updates on their research and learn more about how CBTN is supporting clinical trial development. Register Here: 

For the next annual meeting for 2021, we are targeting May. We are hoping we will once again be able to join with everyone in person to celebrate our accomplishments, see the scientific progress, and look forward to continuing to change the research landscape. We are also planning to hold a CBTN Recognition Dinner the night before the full day meeting. Keep an eye out for any save-the-dates to mark your calendars. 

As a reminder, we encourage you to share the
newsletter subscription link with your personal networks so we can continue to inform the community of the work being done by investigators and patient advocates on behalf of children with brain tumors.

Please find the report for September below. 


-CBTN Executive Committee


Goal: is to increase membership to create the largest pediatric brain tumor resource, with representation across all histologies.

CBTTC now has 25 member sites with the U.S., Australia, Europe, and China represented globally! 7 of those 25 sites are all in varying stages of onboarding. Onboarding includes execution of our master agreement, regulatory approval, training, and the collection of certifications. Our policy is to officially announce a new site once they have executed the agreement and have approved regulatory documents. 

As noted previously, if you identify a hospital that would like to join CBTN, please contact us. We can reach out, provide a background of the consortium and then steps to apply. 

Total Number of Sites (internationally): 25* 
listing of all sites can be found at:
* 18 sites have fully completed regulatory review and site agreement process

New Site Applications in Progress (not yet submitted): 0
New Site Applications: 0
New Sites Recently Approved and Onboarding: 7

  • NYU/Langone Children’s Hospital - Core Member
    • On-boarding Status: Agreement executed, regulatory review in progress
  •  Arnold Palmer Children’s Hospital - Data Satellite
    • On-boarding Status: Agreement executed, regulatory review in progress
  • University of Michigan/CS Mott Children’s Hospital - Data Satellite
    • On-boarding Status: Agreement executed, regulatory review in progress
    St. Louis Children’s - Data Satellite
    • On-boarding Status: Agreement executed, regulatory review in progress
  • Sydney Children’s - Specimen Satellite
    • On-boarding Status: Welcome email was sent and on-boarding begins!
  • University Children's Zürich: Specimen Satellite
    • On-boarding Status: Welcome email was sent and on-boarding begins!
    Doernbecher Children's Hospital - Specimen and Data Satellite
    • On-boarding Status: Welcome email was sent and on-boarding begins!

If you have interest in assisting one of our already existing sites or those now on-boarding, please let us know! Many sites have informed us of what they expect to be upcoming shortfalls for research funding due to COVID-19. We thank all that have donated to CBTN COVID relief needs to ensure all of the CBTN sites continue to move forward full steam this year.


Goal: is to increase membership to create the largest pediatric brain tumor resource, with representation across all histologies.

CBTN consents children and biological parents for participation. For patients, medical information about their brain tumor is collected, as well as biospecimens. For biological parents, only a biospecimen is collected; normally saliva. This is a sample collection that can be done at home and mailed in. Having the family participate is extremely important for research efforts.

The Operations Team has been focused on reducing time and effort to streamline our metric reporting process while also ensuring it is aligned with internal processing of incoming site shipments and CHOP samples. We will be pulling metrics for our multiple reports on the 15th of each month. Due to this recent change, the metrics on the current report will be the same as last month as we are implementing this for October.

  • Total Number of Sites: 25*
    • *18 have been fully on-boarded
  • Overall Total Enrolled
    • All-Time: 4,729
    • FY21: 81
  • Total Children Enrolled
    • All-Time: 3,585
    • FY21: 39
  • Total Mothers Enrolled
    • All-Time: 644
    • FY21: 24
  • Total Fathers Enrolled
    • All-Time: 500
    • FY21: 18

The CBTN collects, manages, and distributes longitudinal clinical data, biospecimens, pre-clinical models, genomic, proteomic, and other data generated from the collected biospecimens. These resources are available for any investigator to request. 

The following is a breakdown of some of the major histological groups (however, more is available). As you all talk with researchers, please let them know these resources are available for their research. All of these have longitudinal clinical data, and as funds become available we generate genomic data, proteomic data, and pre-clinical models. If you have an interest in supporting data generation or pre-clinical model development and drug testing for a specific histology, please let us know. Generation of data and pre-clinical models are critical as they are non-consumptive (unlike biospecimens) and can be used by anyone as many times as needed.

This information will be provided going forward on our website.
You can query the available data here:

Histology    |   Number of Subjects Enrolled with this Diagnosis
  • ATRT - 100
  • DMG - 139
  • Medulloblastoma - 447
  • Low Grade Glioma - 1,011
  • High Grade Glioma - 349
  • Ependymoma - 325
  • Craniopharyngioma - 130
  • Dysembryoplastic Neuroeithelial Tumor (DNET) - 79
  • Ganglioglioma - 188

A heartfelt thank you again to all of you that have recently donated to provide COVID relief to keep all of the CBTN sites and CBTN Operations moving forward. We will be following up with the slides highlighting key information from the FY20 budget report provided and a simplified overview of FY20, FY21, FY22 financials. Please provide any questions or comments to Jena Lilly. 

Budget Q&A
What are the budget expenses for CBTN? 

  • CBTN Operations Personnel/ Sites Personnel/ Lab supplies/ Communications and Meetings

What are the funding sources for CBTN and how are they monitored? 

  • Institutional support from CHOP, Federal and Philanthropic Funding

What is CBTN's plan for sustainability, growth and fiscal oversight?

  • Increase federal funding and engage commercial partnerships to support operations in a sustainable model
  • Fundraise locally to support sites
  • Maintain and grow philanthropy for research and clinical translational projects.
  • Institute performance metrics to monitor site funding levels, budget reports approved by leadership and foundations for approval

What is the fiscal year?

  • July 1 to June 30
  • Secured funding for the next fiscal year (July 1, 2021+) will occur during current FY

Where do I send funding to and how should I ensure it is directed to CBTN?

  • CBTN is not a 501 3c but as Operations are at CHOP uses CHOP as our legal and financial management system
  • CHOP does not take any overhead on donations
  • Funding raised by CHOP or sent to CHOP is distributed per donor intent

How does site funding work?
Does CBTN subcontract to the primary sites?

  • Yes, subcontracts with the sites are legal agreements for the work they will perform for CBTN
  • Funding for the sites and operations needs to be secured before June 30th of the fiscal year. 

Current CBTN Grant Submissions and Awards:
NIH grant submissions

  • NCI Pediatric Brain Tumor SPORE submitted notification late 2021
  • DOD “Rare Cancers Research Program Resource and Community Development Award” submission Nov 2020

KEY HIGHLIGHTS: CBTN has collaborated on 175 research projects with over 100 investigators across 9 countries. 50 are CBTN investigators and over 70 are non-CBTN investigators. This includes three collaborations with the PNOC disease working groups for the pre-clinical work required for the development of a new clinical trial.

Our FY21 goal is to have 30 new approved biospecimen requests. As of October 1, we have had 5 new projects approved. In an attempt to increase the utilization of biospecimens, CBTN has recruited additional scientific experts to review proposals and formed two committees. You can find information on these projects here

All-time total number of requests: 79

  • 65 total requests approved
    • 48 sample requests approved
    • 17 cell line requests approved
  • 4 requests changed to data access requests (data was already generated)
  • 4 requests were withdrawn from consideration by the investigator
  • 4 requests are being reviewed by the operations center for sample availability
  • 2 requests are with the investigator for revisions or under further review

Our goal is to increase the number of requests and utilization of data. In addition, we aim to have 60 new data projects, and as of October 1, we have had 10 new projects approved. Additionally, “processed data” is available anytime without request has been utilized thousands of times. You can find more information on the data projects here

  • 112 total requests approved


OPEN PBTA landscape analysis phase one is complete and the goal is to finalize a paper in 2020. All data are available and a request was sent out for anyone to contribute to the manuscript and analysis.


We are looking for opportunities to empower and accelerate brain tumor research. Please let us know if there any other researchers you’ve connected with that you would like us to reach out to?


CBTN has several key publications occurring now, with new submission to 12 different scientific journals.

Total Accepted: 17

  1. Aubin, Rachael, Emma C. Troisi, Adam N. Alghalith, Maclean P. Nasrallah, Mariarita Santi, and Pablo G. Camara. 2020. “Cell Ecosystem and Signaling Pathways of Primary and Metastatic Pediatric Posterior Fossa Ependymoma.”

  2. Bjork, I., Peralez, J., Haussler, D., Spunt, S.L., Vaske, O.M. 2019. Data sharing for clinical utility. Cold Spring Harbor Molecular Case Studies . Oct 23;5(5), pii: a004689

  3. Bobyn, A., Zarrei, M., Zhu, Y., Hoffman, M., Brenner, D., Resnick, A. C., Scherer, S. W., & Gallo, M. (2020). Ancestry and frequency of genetic variants in the general population are confounders in the characterization of germline variants linked to cancer. BMC medical genetics, 21(1), 92.

  4. Connors, M., W. Paden, P. B. Storm, A. J. Waanders, and S. S. Lang. 2019. 'Low-grade astrocytoma in the setting of a developmental venous anomaly', Childs Nerv Syst.

  5. Dang, Mai T, Michael Gonzalez, Krutika S Gaonkar, Komal S Rathi, Patricia Young, Sherjeel Arif, Li Zhai, Md Zahidul Alam, Samir Devalaraja, and Tsun Ki To. 2020. 'Single-cell transcriptomic profile reveals macrophage heterogeneity in medulloblastoma and their treatment-dependent recruitment', BioRxiv.

  6. Gaonkar, Krutika S., Komal S. Rathi, Payal Jain, Yuankun Zhu, Miguel A. Brown, Bo Zhang, Pichai Raman, Phillip B. Storm, John M. Maris, Adam C. Resnick, Jaclyn N. Taroni, and Jo Lynne Rokita. 2019. 'annoFuse: an R Package to annotate and prioritize putative oncogenic RNA fusions', BioRxiv: 839738

  7. Hoffman, M., A. H. Gillmor, D. J. Kunz, M. J. Johnston, A. Nikolic, K. Narta, M. Zarrei, J. King, K. Ellestad, N. H. Dang, F. M. G. Cavalli, M. M. Kushida, F. J. Coutinho, Y. Zhu, B. Luu, Y. Ma, A. J. Mungall, R. Moore, M. A. Marra, M. D. Taylor, T. J. Pugh, P. B. Dirks, D. Strother, L. Lafay-Cousin, A. C. Resnick, S. Scherer, D. L. Senger, B. D. Simons, J. A. Chan, A. S. Morrissy, and M. Gallo. 2019. 'Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma', Cancer Res, 79: 2111-23.

  8. Ijaz, H., M. Koptyra, K. S. Gaonkar, J. L. Rokita, V. P. Baubet, L. Tauhid, Y. Zhu, M. Brown, G. Lopez, B. Zhang, S. J. Diskin, Z. Vaksman, J. L. Mason, E. Appert, J. Lilly, R. Lulla, T. De Raedt, A. P. Heath, A. Felmeister, P. Raman, J. Nazarian, M. R. Santi, P. B. Storm, A. Resnick, A. J. Waanders, and K. A. Cole. 2020. ‘Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTN) and Pediatric Brain Tumor Atlas (PBTA)’ , Neuro Oncol, 22: 163-65.

  9. Ijaz, Heba, Mateusz Koptyra, Krutika S. Gaonkar, Jo Lynne Rokita, Valerie P. Baubet, Lamiya Tauhid, Yankun Zhu, Miguel Brown, Gonzalo Lopez, Bo Zhang, Sharon J. Diskin, Zalman Vaksman, Jennifer L. Mason, Elizabeth Appert, Jena Lilly, Rishi Lulla, Thomas De Raedt, Allison P. Heath, Alex Felmeister, Pichai Raman, Javad Nazarian, Maria Rita Santi, Phillip B. Storm, Adam Resnick, Angela J. Waanders, and Kristina A. Cole. 2019. 'Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTN) and Pediatric Brain Tumor Atlas (PBTA)', BioRxiv: 656587.

  10. Petralia, Francesca, Nicole Tignor, Boris Reva, Pichai Raman, Shrabanti Chowdhury, Dmitry Rykunov, Azra Krek, et al. 2020. “Abstract 445: Integrated Proteogenomic Characterization across Seven Histological Types of Pediatric Brain Tumors.” Cancer Research 80 (16 Supplement): 445–445.

  11. Pfeil, J., Sanders, L.M., Anastopoulos, I., et al. 2020. Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures. PLoS Comput Biol,16(4):e1007753. doi:10.1371/journal.pcbi.1007753

  12. Rivero-Hinojosa S, Kinney N, Garner HR, Rood BR. ‘Germline microsatellite genotypes differentiate children with medulloblastoma’, Neuro-Oncology. 2020 Jan 11;22(1):152-62.

  13. Sanders, L.M., Rangaswami, A., Bjork, I., Lam, D.L., Beale, H.C., Kephart E.T., Durbin, A., Learned, K., Currie, R. A., Lyle, G., Pfeil, J., Shah, A.T., Lee, A.G., Leung, S.G., Behroozfard, I.H, Breese, M.R., Peralez, J., Hazard, F.K, Lacayo, N., Spunt, S.L., Haussler, D., Salama, S.R., Sweet-Cordero, E.A., and Vaske, O.M. 2019. Comparative RNA-seq analysis aids in diagnosis of a rare pediatric tumor. Molecular Case Studies.Oct 23;5(5), pii: a004317

  14. Steidle, E. A., V. A. Morrissette, K. Fujimaki, L. Chong, A. C. Resnick, A. P. Capaldi, and R. J. Rolfes. 2020. 'The InsP7 phosphatase Siw14 regulates inositol pyrophosphate levels to control localization of the general stress response transcription factor Msn2', J Biol Chem, 295: 2043-56.

  15. Surrey, L. F., P. Jain, B. Zhang, J. Straka, X. Zhao, B. N. Harding, A. C. Resnick, P. B. Storm, A. M. Buccoliero, L. Genitori, M. M. Li, A. J. Waanders, and M. Santi. 2019. 'Genomic Analysis of Dysembryoplastic Neuroepithelial Tumor Spectrum Reveals a Diversity of Molecular Alterations Dysregulating the MAPK and PI3K/mTOR Pathways', J Neuropathol Exp Neurol, 78: 1100-11.

  16. Vaske, O.M., Bjork, I., Salama, S.R., et al. 2019. Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. JAMA Netw Open, 2(10):e1913968. doi:10.1001/jamanetworkopen.2019.13968

  17. Vaske, O.M. and Haussler, D. 2019. Data sharing for pediatric cancers. Science, 363(6432):1125

Total Currently Submitted: 4
  1. Submitted an abstract entitled “Discovering genetic interactions in the CBTTC dataset” for BioSB2020, a Dutch conference with focus on bioinformatics and systems biology. Abstract selected for a poster presentation. Conference originally scheduled for 21-22 April 2020, but now postponed to 27-28 October 2020. More information:"
  2. Submitted an abstract titled “Reconstructing the Gene Regulatory Landscape of Pediatric BrainTumors” to the 2020 ISMB meeting (Regulatory and Systems Genomics track)
  3. Payal Jain, Lea F. Surrey, Joshua Straka, Pierre Russo, Richard Womer, Marilyn M. Li, Phillip B. Storm, Angela Waanders, Michael D. Hogarty, Adam Resnick, Jennifer Picarsic. ‘Novel BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers’. (Submitted to Cancer Research, May 2020)
  4. The Immunogenomic Landscape of Primary Pediatric Solid Tumours- (Submitted to Cancer Cell)
Pending Submission: 5
  1. High-grade glioma cell line models for pediatric cancer. Mateusz Koptyra, Komal S. Rathi, Valerie Baubet, Jo Lynne Rokita
  2. OPEN PBTA Manuscript is on track, goal pre-print Sept 2020
  3. CBTTC Resource Paper being reviewed submission to J Neuro-Oncology and Neurosurgery goal Sept 2020
  4. A Transcriptome-based Classifier to Determine Molecular Subtypes in Medulloblastoma.
  5. Ammar S. Naqvi, Brian Ennis, Krutika S. Gaonkar, Michael Koldobskiy, Yuankun Zhu, Miguel A. Brown, Bo Zhang, Phillip B. Storm, Adam C. Resnick, Jo Lynne Rokita (2020). “Molecular mechanisms and functional impact of aberrant splicing in diffuse intrinsic pontine gliomas”.

5 Abstracts accepted
  1. Ammar S. Naqvi, Brian Ennis, Krutika S. Gaonkar, Michael Koldobskiy, Yuankun Zhu, Miguel A. Brown, Bo Zhang, Phillip B. Storm, Adam C. Resnick, Jo Lynne Rokita (2020). “Molecular mechanisms and functional impact of aberrant splicing in diffuse intrinsic pontine gliomas”. ABSTRACT #446. RNA 2020 on-line meeting.
  2. Payal Jain presented to the AACR virtual meeting (June 22-24). Her abstract was #6746: Novel BRAF gene fusions in pediatric histiocytic neoplasms respond differently to RAF targeted therapies based on dimerization profiles.
  3. Lauren M. Sanders, A. Geoffrey Lyle, Holly C. Beale, Ellen Towle Kephart, Katrina Learned, Jacob Pfeil, Jennifer Peralez, Norman Lacayo, Arun Rangaswami, Sheri L. Spunt, Isabel Bjork, David Haussler, Sofie R. Salama, Olena M. Vaske, "Comparative gene expression analysis for identification and prioritization of therapeutic targets in a cohort of childhood cancers." Poster, AACR Advances in Pediatric Cancer Research Conference, Montreal, September 2019.
  4. Olena M. Vaske. Data Federation Approaches in Treehouse Childhood Cancer Initiative. Invited Talk. Childhood Cancer Data Initiative Symposium, Washington, DC, July 2019.
  5. Submitting an abstract to the AACR conference "Tumor heterogeneity: from single cells to clinical impact" to be held in Philadelphia on September 10-13. Preparing a manuscript entitled "Cell Ecosystem and Signaling Pathways of Posterior Fossa Childhood Ependymoma Revealed by Single-Cell Transcriptomic Profiling", - plan to submit for publication this fall.
Currently the CBTN has 70+ cell lines that are available for pre-clinical testing. To enhance these pre-clinical models researchers perform genomic testing WGS and RNA Seq on the cell lines in addition to the tumor samples. Currently, this genomic characterization has begun for specific brain tumor types but is funding-dependent to continue. Please reach out to Jena Lilly ( if you would like to sponsor.


There are seven CBTN/PNOC working groups - Medulloblastoma, DMG, ATRT, LGG, Ependymoma, Craniopharyngioma and Imaging. Each working group has their own goals and they convene once every month and collaborate on preclinical and clinical research. The groups are facilitated with CBTTC by allowing for sharing of resources, clinical data, biospecimens, preclinical models and genomic and proteomic data that can be used to develop new data-driven clinical trials. If you would like to participate or learn more please contact Ryan Velasco (

Medulloblastoma Leads: 

  • Robert Wechsler-Reya, PhD; Sanford Burnham Prebys
  • Tabitha Cooney, MD; UCSF Benioff Children’s Hospital

Craniopharyngioma  Leads: 

  • Cassie Kline, MD; Children's Hospital of Philadelphia
  • Fatema Malbari, MD; Texas Children’s Hospital

LGG leads: 

  • Angela Waanders, MD, MPH; Ann & Robert H. Lurie Children’s Hospital of Chicago
  • Daphne Adele Haas-Kogan, MD; Dana-Farber Cancer Institute
  • Pratiti Bandopadhayay, MBBS, PhD; Dana-Farber Cancer Institute
  • Joanna Phillips, MD, PhD; UCSF Helen Diller Family Comprehensive Cancer Center

ATRT leads: 

  • Ashley Margol, MD, MS; Children’s Hospital Los Angeles
  • Annie Huang, MD, PhD, FRCP(C); The Hospital for Sick Kids
  • Eric Raabe, MD, PhD; Johns Hopkins School of Medicine.

Ependymoma leads: 

  • Eugene Hwang, MD; Children’s National Health System
  • Mariella Filbin, MD, PhD; Dana-Farber Cancer Institute
  • Steven Mack, PhD; Texas Children's Hospital
  • Derek Hanson, MD; Hackensack Meridian Health

DMG leads:

  • Sabine Mueller, MD, PhD; UCSF Benioff Children’s Hospital
  • Javad Nazarian, PhD; University Children’s Hospital of Zurich]
Imaging Working Group leads:
  • Josh Rubin, MD, PhD; Washington University School of Medicine, St. Louis
  • Javier Villaneuva-Meyer, MD; University of California, San Francisco
  • S. Ali Nabavizadeh, MD; Hospital of the University of Pennsylvania 

Do you need any resources, collateral materials, or participation from the CBTN for any scheduled event or any other activity.

CBTN Website Launch
In October, we’re excited to officially launch the new Children’s Brain Tumor Website ( to the public! We will be hosting an official launch of the website in the coming weeks. To prepare for this launch, we would love to have you each review the website and provide comments and feedback to our development team. We want this website to be a powerful resource to the scientific community and allow users to learn more about the CBTN projects and initiatives. 

DISCLAIMER: The website is live on, but is not currently visible on Google search tools, so please do not share this link publicly until we have officially launched the website domain.

To provide feedback on the website, visit and select the blue “Feedback” tab on the right-hand side for each page within your browser window.

You’ll be able to select the area of the page and enter your feedback, along with an opportunity to provide your email address. This will allow us to follow up with you individually if we have questions regarding the feedback you provided. Once you have completed your comments, select “Submit” and a ticket will be created for our development team to review. 

We’re working to improve many of the site’s features, including adding additional images and graphics, but we’d love to know what could make the website a useful resource for your organization. We’re tentatively planning to launch the website in mid October (10/19) for the initial release. Additional features are also being identified for V2 development by the end of December 2020. Please stay tuned for updates and additional features! Thank you in advance for your feedback. 

Brand Development Updates:
Please click the link below to view the CBTN brand style guide. This style guide defines the CBTN’s brand standards and will be used as a reference in creating all CBTN branded handouts, infographics, videos and other collateral materials. This is intended for CBTN internal use as well as working to create materials with external vendors, agencies and member institutions. 

View the style guide

We’ve also begun creating a library of CBTN print and digital resources - more of these assets including one-pagers and infographics will be shared with you over the coming weeks and months and will form a toolkit for foundations and other groups to use to share about the CBTN’s research. 

If you have suggestions or feedback for website features to include, perhaps from other websites you’ve especially liked, please contact us at


Social Media Metrics - September 2020:

  • Audience Reach: 2,510 users (2,858 impressions)
  • Users Directly Engaged: 209
  • Engagement Rate: 8.32% (1-3%: industry avg.)
  • Followers Gained: 11
Current Followers: 591


  • Audience Reach: 5,447 users
  • Users Directly Engaged: 219
  • Engagement Rate: 4.02% (0.33% industry avg.)
  • Followers Gained: 9
Current Followers: 618

CBTTC Website Traffic - September 2020:

  • 757 Unique Users (86.1% New Users)
  • 899 Sessions
  • 1,469 Pageviews

Question: How are samples used?

Answer: Scientists use the tissue samples to study how the tumor works by looking at its genes and proteins. These specimens play a critical role in our emerging understanding of how these tumors work. For example, studying samples from breast cancer patients helped researchers create a test to identify breast cancer types, create new treatments, and customize treatments.
Did you miss one of our last CBTN Foundation Partners Reports? You can access them here!
Follow us on Twitter
Follow us on Facebook
Visit our Website
Copyright © 2020 Children's Hospital of Philadelphia/Center for Data-Driven Discovery in Biomedicine, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp